R&D Trends

Soligenix, SciClone collaborate in personalized medicine

Monday, July 8, 2013 12:00 PM

Soligenix, a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there is an unmet medical need, has announced a personalized medicine collaboration with SciClone Pharmaceuticals in the company's oral mucositis clinical program with SGX942. Soligenix will receive access to SciClone's oral mucositis clinical and regulatory data library in exchange for commercialization rights in China, including Hong Kong and Macau.

More... »

Avanir, OptiNose in licensing deal

Wednesday, July 3, 2013 02:13 PM

Avanir Pharmaceuticals and OptiNose have entered into an exclusive North American license agreement for the development and commercialization of OptiNose's novel Breath Powered intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine. If approved, this product would be the first dry-powder nasal delivery form of sumatriptan.

More... »

Janssen, J&J Innovation ally with The Icahn School Of Medicine at Mount Sinai

Wednesday, July 3, 2013 12:30 PM

Janssen Biotech and Johnson & Johnson Innovation have established a research alliance with The Icahn School of Medicine at Mount Sinai to advance the scientific understanding of inflammatory bowel disease (IBD) and the discovery of next generation therapeutic solutions.

More... »

Roche Diagnostics acquires Constitution Medical

Wednesday, July 3, 2013 12:00 PM

Roche Diagnostics has acquired Boston-based Constitution Medical Investors (CMI). CMI developed a hematology testing system designed to provide faster and more accurate diagnosis of blood-related diseases, which would improve patient care. Roche will pay CMI shareholders $220 million upfront, as well as further contingent payments depending on the achievement of certain milestones. CMI will serve as a center of excellence in the field of hematology within Roche.

More... »

Royal Philips, GRMC sign 15-year alliance

Wednesday, July 3, 2013 11:00 AM

Royal Philips and Georgia Regents Medical Center (GRMC), Georgia’s public academic health center, have announced a 15-year alliance to enable patient-centered approaches to care and to create a business model that addresses current and future clinical, operational and equipment needs of GRMC sites.

More... »

Heptares grants Shire worldwide NDC license

Wednesday, July 3, 2013 10:00 AM

Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares Therapeutics, currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.

More... »

Seattle Genetics, Agensys to co-develop ADC

Wednesday, July 3, 2013 09:30 AM

Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under an existing ADC collaboration agreement with Agensys, an affiliate of Tokyo-based Astellas Pharma. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is expressed on bladder and lung cancer.

More... »

Texas A&M launches Whole Systems Genomics Initiative

Wednesday, July 3, 2013 08:37 AM

Texas A&M University has announced the Whole Systems Genomics Initiative (WSGI), a strong faculty-conceived program developed as part of the Chancellor's Research Initiative (CRI) to define the future of genomic science, enabling researchers to address some of the most pressing challenges facing modern society through innovative and collaborative scholarly programs.

More... »

Roche, AstraZeneca launch early research data-sharing consortium

Tuesday, July 2, 2013 01:24 PM

Roche and AstraZeneca are collaborating to share early research data related to drug design to further accelerate discovery of high-quality compounds with an increased chance of clinical success.

More... »

Immunocore, Genentech collaborate on cancer targets

Tuesday, July 2, 2013 01:17 PM

Immunocore, an Oxford-based biotechnology company developing novel biological drugs known as ImmTACs to treat cancer and viral disease, has entered a research collaboration and licensing agreement with Genentech, a member of the Roche Group, for the discovery and development of multiple novel cancer targets using Immunocore's ImmTAC technology.

More... »